Comparative Pharmacology
Head-to-head clinical analysis: HUMULIN R versus HUMULIN R KWIKPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMULIN R versus HUMULIN R KWIKPEN.
HUMULIN R vs HUMULIN R KWIKPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Human insulin is identical to endogenous insulin. It binds to insulin receptors on target cells, activates tyrosine kinase signaling, and promotes glucose uptake, glycogenesis, lipogenesis, and protein synthesis while inhibiting gluconeogenesis and glycogenolysis.
Insulin lispro lowers blood glucose by binding to insulin receptors, increasing glucose uptake in skeletal muscle and adipose tissue, and inhibiting hepatic glucose production.
Subcutaneous: 0.2-0.6 units/kg/day divided into 2-3 doses, individualized. Intravenous: Insulin infusion protocols for hyperglycemia.
Subcutaneous injection, individualize based on metabolic needs and blood glucose monitoring. Typical starting total daily insulin dose in type 1 diabetes: 0.5-1 unit/kg/day, with 50-60% as basal and 40-50% as prandial. In type 2 diabetes, initial total daily dose: 0.2-0.4 units/kg/day, with adjustments. Administer 30 minutes before meals.
None Documented
None Documented
Terminal elimination half-life: 0.5-1 hour (intravenous); prolonged in renal impairment (up to 3-4 hours).
5-10 minutes (intravenous); subcutaneous: 1.5-2 hours (depot absorption-limited).
Primarily renal (>90% as unchanged drug after degradation), with minor biliary/fecal elimination (<10%).
Renal: 60-80% (metabolized to inactive peptides); hepatic metabolism via insulin-degrading enzyme; remainder reabsorbed in proximal tubule.
Category C
Category C
Human Insulin
Human Insulin